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Abstract
Introduction Sex steroids, insulin-like growth factors (IGFs) and
prolactin are breast cancer risk factors but whether their effects
are mediated through mammographic density, one of the
strongest risk factors for breast cancer, is unknown. If such a
hormonal basis of mammographic density exists, hormones may
underlie ethnic differences in both mammographic density and
breast cancer incidence rates.
Methods In a cross-sectional study of 270 postmenopausal
Caucasian and Afro-Caribbean women attending a population-
based breast screening service in London, UK, we investigated
whether plasma biomarkers (oestradiol, oestrone, sex hormone
binding globulin (SHBG), testosterone, prolactin, leptin, IGF-I,
IGF-II and IGF binding protein 3 (IGFBP3)) were related to and
explained ethnic differences in mammographic percent density,
dense area and nondense area, measured in Cumulus using the
threshold method.
Results Mean levels of oestrogens, leptin and IGF-I:IGFBP3
were higher whereas SHBG and IGF-II:IGFBP3 were lower in
Afro-Caribbean women compared with Caucasian women after
adjustment for higher mean body mass index (BMI) in the former
group (by 3.2 kg/m2 (95% confidence interval (CI): 1.8, 4.5)).
Age-adjusted percent density was lower in Afro-Caribbean
compared with Caucasian women by 5.4% (absolute
difference), but was attenuated to 2.5% (95% CI: -0.2, 5.1)
upon BMI adjustment. Despite ethnic differences in biomarkers
and in percent density, strong ethnic-age-adjusted inverse
associations of oestradiol, leptin and testosterone with percent
density were completely attenuated upon adjustment for BMI.
There were no associations of IGF-I, IGF-II or IGFBP3 with
percent density or dense area. We found weak evidence that a
twofold increase in prolactin and oestrone levels were
associated, respectively, with an increase (by 1.7% (95% CI: -
0.3, 3.7)) and a decrease (by 2.0% (95% CI: 0, 4.1)) in density
after adjustment for BMI.
Conclusions These findings suggest that sex hormone and IGF
levels are not associated with BMI-adjusted percent
mammographic density in cross-sectional analyses of
postmenopausal women and thus do not explain ethnic
differences in density. Mammographic density may still,
however, be influenced by much higher premenopausal
hormone levels.
BMI: body mass index; CI: confidence interval; ELISA: enzyme-linked immunosorbent assay; IGF: insulin-like growth factor; IGFBP: insulin-like growth 
factor binding protein; SHBG: sex-hormone binding globulin; SNP: single nucleotide polymorphism.Breast Cancer Research    Vol 11 No 3    McCormack et al.
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Introduction
Mammographic density, the percentage of a mammogram that
appears as radio-dense fibroglandular tissue, is one of the
strongest markers of subsequent breast cancer risk [1]. This
density may reflect an underlying process occurring within the
breast that is causally related to breast cancer. Dense tissue
is thought to occur as a consequence of higher rates of stro-
mal and epithelial proliferation, factors that increase the risk of
somatic mutations, epigenetic alterations and carcinogenesis
[2]. Some endogenous sex steroids and growth factors are
established breast cancer risk factors. Many of these are
involved in epithelial cell proliferation and thus are potential
drivers of the association between mammographic density
and breast cancer risk. Candidate biomarkers are oestrogens,
progesterone, testosterone, prolactin and premenopausal lev-
els of insulin-like growth factor (IGF)-I [3-5]. Leptin may have a
role in breast cancer development, especially in postmenopau-
sal women where body mass index (BMI) is a breast cancer
risk factor [6].
Two observations support a hormonal basis for mammo-
graphic density: density increases upon use of oestrogen and
progestin hormonal therapies; and density is reduced by
tamoxifen, a selective oestrogen receptor modulator [7,8]. Elu-
cidating the biological processes that give rise to increased
mammographic density might help identify ways in which this
risk factor and ultimately breast cancer risk might be lowered.
To date, however, studies that have examined the association
between such biomarkers and density have revealed predom-
inantly null or inconsistent associations. Their findings may
have been limited by lack of adequate heterogeneity in biomar-
ker or breast density distributions as most studies were con-
ducted in relatively homogeneous populations. We try to
overcome this by studying these associations in a heterogene-
ous multiethnic group of native and first-generation migrant
women in the UK.
We have investigated mammographic density in relation to
breast cancer biomarkers in an ethnically diverse study popu-
lation. We recently reported that, consistent with their lower
breast cancer risk nationally, the mean percentage mammo-
graphic density was lower in Afro-Caribbean women com-
pared with Caucasian women [9] within our UK study
population. This difference was largely explained by anthropo-
metric and reproductive factors, whose influence on density
may be mediated by plasma breast cancer biomarkers. Alter-
natively such biomarkers may be independently related to
mammographic density [10-12]. We investigated these
hypotheses here in a group of first-generation Afro-Caribbean
women and native Caucasian women in the UK. The study
aims were to assess: first, whether sex hormones, leptin, prol-
actin and IGFs are associated with mammographic density;
second, whether there are ethnic variations in the distribution
of these biomarkers; and third, if the first two aims hold true,
whether variations in biomarker levels explain ethnic differ-
ences in mammographic density.
Materials and methods
Study population
We conducted a study of ethnic variations in mammographic
density in the UK (as described elsewhere [9]). In brief, in
2005 and 2006 we randomly sampled an ethnically stratified
group of women from the Central and East London Breast
Screening Service who had undergone their second or further
routine screening mammogram in 2004 at ages 50 to 65
years. The invitation to participate was mailed to women on
average 1.5 years after their last mammogram, a strategy
employed so as not to jeopardise breast screening uptake. In
this population-based screening programme, three ethnic
groups were included based on previously self-assigned eth-
nicity data: Caucasian (for those who selected 'White UK'),
South Asian, and Afro-Caribbean ('African', 'Afro-Caribbean',
'Black African', Black-other' or 'Black Caribbean').
The randomly selected participants in each ethnic group were
sent a questionnaire to self-complete, providing information on
ethnicity, country of birth and known lifestyle breast cancer risk
factors – that is, age at menarche, age at first full-term preg-
nancy, parity, total duration of breast feeding, past use of hor-
mone therapy and oral contraceptives, alcohol use, smoking,
height and weight – which were used to calculate the BMI as
weight (kg)/height2 (m2). Participants also provided consent
for their mammograms to be digitised. Nonresponders were
re-contacted (by post and by telephone) after 6 and 10 weeks
to further increase participation rates.
After returning their questionnaire, postmenopausal Cauca-
sian and Afro-Caribbean women not taking hormonal thera-
pies were also asked to optionally have a 19 ml blood sample
taken by their general practitioner, from which plasma and
buffy coat was obtained and stored at -80°C. South Asian
women were not asked to provide blood as in doing so we
might have further compromised the very low response rate in
this group [9]. The study was approved by the East London
and The City Local Research Ethnics Committee.
With response rates of 59% and 41%, respectively, 267 Cau-
casian women and 213 Afro-Caribbean women participated in
total. Of these women, 152 (56.9%) and 118 (55.3%),
respectively, also provided a blood sample.
Assays
Plasma levels of sex hormones were analysed at the Academic
Department of Biochemistry, Royal Marsden Hospital Labora-
tories, London UK. Total oestradiol and oestrone were meas-
ured by an inhouse radioimmunoassay with a prior organic
extraction. The lower detection limit was 3.0 pmol/l (no sam-
ples fell below this level). Testosterone was quantified using a
coat-a-count method (Siemens Diagnostics formally known asAvailable online http://breast-cancer-research.com/content/11/3/R38
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DPC, Deerfield, IL, US) with a lower detection limit of 0.14
nmol/l (nine samples), sex hormone binging globulin (SHBG)
was quantified using Spectria SHBG IRMA 68562 (Orion
Diagnostica, Espoo, Finland) with a lower detection limit of 1.3
nmol/l (all samples were higher) and prolactin using DSL-
4500 (Diagnostic Systems Laboratories, Webster, TX, US)
with a lower detection limit of 27 mIU/l (all levels exceeded
this). Leptin was measured using a solid-phase radioimmu-
noassay kit (DSL 23100i) from Beckman Coulter (High
Wycombe, UK); the lower detection limit was 0.5 ng/ml and all
levels were higher. Plasma IGF-I was measured using an
ELISA assay (Diagnostic Systems Laboratories, Webster, TX,
USA), IGF binding protein 3 (IGFBP3) was measured using a
double-antibody radioimmunoassay, and IGF-II by an inhouse
radioimmunoassay method (iodination of IGF-II) at the Univer-
sity of Bristol (laboratory of Prof. J Holly). Laboratory staff were
blind to any identifiable data for the women. Free oestradiol
was calculated from total oestradiol and SHBG [13]. Plasma
levels less than the lower detection limit were assumed to have
the value of this limit.
For sex hormones, 11 quality control samples (from one indi-
vidual who was not a participant in this study) were included
to assess repeatability. Intraclass correlation coefficients were
0.98 (95% confidence interval (CI): 0.97, 1.00) for oestradiol,
0.63 (95% CI: 0.31, 0.96) for oestrone, 0.80 (95% CI: 0.62,
0.98) for testosterone, 0.97 (95% CI: 0.95, 1.00) for SHBG
and 0.67 (95% CI: 0.37, 0.96) for prolactin. Measurement
errors for IGFs are also known to be low/moderate, with coef-
ficients of variation of 6.6%, 12.0% and 3.9% for IGF-I, IGF-II
and IGFBP3, respectively [14]. The IGF-I:IGFBP3 and IGF-
II:IGFBP3 molar ratios were calculated by firstly converting
IGF-I and IGF-II weights to molecular concentrations (dividing
by their molecular weights of 0.13 and 0.025, respectively).
Mammographic density
Density measurements from the 2004 breast screening round
were analysed as this was the closest to the time of blood
draw. All four films (cranio-caudal and medio-lateral oblique
views for each breast) were digitised on an Array 2905 digi-
tiser (optical density, 0 to 4.0; 75 μm; Array Corporation
Europe, Roden, The Netherlands). The mammographic density
was assessed by a single observer (VAM) using Cumulus, an
interactive thresholding programme [15]. The nondense,
dense and total breast areas in square centimetres, as well as
the percentage mammographic density (100 × dense area/
total area), were analysed. Films were read in randomly sorted
batches of 200. One hundred films were independently re-
read by the same observer and the reliability of a single density
reading was 0.90.
Statistical methods
We investigated whether ethnic variations existed in biomarker
levels (second study aim) and then whether plasma biomark-
ers were associated with measures of mammographic density
(first study aim) – and, if so, whether ethnic differences in
these biomarkers (examined in the first stage) might explain
ethnic variations in mammographic density (third study aim).
Firstly, normal error regression models were used to assess
the association of ethnic group (a binary indicator variable)
with each biomarker, incorporating a natural logarithmic trans-
formation of oestradiol, oestrone, SHBG, prolactin, testoster-
one, IGF-I, IGF-II and IGFBP3 to improve normality of residuals
(second study aim). For these log-transformed biomarkers,
their effects are thus in relative (percentage) terms. Adjust-
ment for the laboratory batch (categorical variable) and age at
blood collection (linear term) were included in these and all fur-
ther models that included biomarkers. To avoid the over-influ-
ence of excessively raised biomarker levels in some women
due to particular illnesses that might distort general associa-
tions, outliers were removed. Only prolactin had such an out-
lier, with a value of over 3,000 mIU/l (hyperprolactinaemia).
The minimum detectable difference in mean biomarker levels
between the two ethnic groups (n = 270) was 0.35 standard
deviations (80% power, 5% false positive probability).
For the second and third study aims, where mammographic
measures (percent density, dense area and nondense area)
were the outcome, the average of the estimates from all four
films on the square-root scale was calculated for each meas-
ure, providing a repeatable estimate of density (intraclass cor-
relation coefficients of 0.97, 0.97, 0.98 and 0.99 for percent
density, dense area, nondense area and total breast area,
respectively). In these analyses, to provide more meaningful
estimates of associations with density, effects of explanatory
variables were referred to reference values of 16% density,
and dense, nondense and total breast areas of 22, 118 and
140 cm2, respectively (median values in Caucasians, the ref-
erence group); the percent differences in density are thus dif-
ferences on the absolute (not relative) scale of density
measurement. We assessed whether biomarkers were related
to mammographic density both using quintiles and using a lin-
ear trend of biomarker data (second study aim).
For all regression models, normal quintile plots and Cook's dis-
tances were examined to check the normality assumption and
to identify outliers.
Results
In total, 270 women provided blood samples. All 152 Cauca-
sian women were born in the UK, and most of the 118 Afro-
Caribbean women were born in the Caribbean (64%) or West
Africa (30%) and came to the UK at a mean age of 20.9 years
(standard deviation, 9.0). Within each ethnic group, women
donors had similar characteristics to women who did not pro-
vide blood, with the exception of a higher participation rate
among Afro-Caribbean women with a family history of breast
cancer. Age at mammography ranged from 52 to 65 years and
blood samples were taken on average 1.70 years later (95%
reference range, 0.9 to 2.5 years), with no difference betweenBreast Cancer Research    Vol 11 No 3    McCormack et al.
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Table 1
Distributions of breast cancer risk factors and breast cancer biomarkers by ethnic group
Caucasian women (n = 152) Afro-Caribbean women (n = 118)
Lifestyle breast cancer risk factorsa
Age at mammography (years) 57.8 (3.3) 58.1 (3.6)
Age arrived in UK (years) - 20.9 (9.0)
Age at menarche (years) 12.7 (1.5) 13.5 (2.0)
Percentage nulliparous 22.2 6.0
Age at first birth (years) 24.4 (5.8) 22.2 (5.2)
Age at menopause (years) 50.1 (4.8) 48.3 (5.4)
Body mass index (kg/m2) 26.2 (5.4) 29.4 (5.4)
Percentage previous hormone therapy use (ever) 35.5 24.6
Percentage previous oral contraceptive use (ever) 72.2 40.4
Percentage alcohol drinkers 86.1 57.4
Percentage current smokers 13.3 4.3
Percentage family history of breast cancer 17.8 11.9
Mammographic measuresb
Mammographic density (%) 16.2 (8.9 to 24.5) 8.3 (4.3 to 19.8)
Dense area (cm2) 21.2 (11.9 to 35.7) 17.3 (8.4 to 31.3)
Nondense area (cm2) 116.9 (86.7 to 160.0) 167.9 (115.3 to 235.9)
Total breast area (cm2) 141.5 (108.1 to 193.3) 195.2 (140.2 to 261.5)
Plasma biomarkersc
Leptin (ng/ml) 12.3 (11.1, 13.5)d 19.1 (17.5, 20.7)c
Oestradiol (pmol/l) 21.7 (19.6, 23.9) 29.0 (25.6, 32.9)
Free oestradiol (pmol/l) 0.31 (0.27, 0.34) 0.44 (0.38, 0.50)
Oestrone (pmol/l) 72.9 (68.0, 78.2) 82.2 (74.9, 90.3)
Sex hormone binding globulin (nmol/l) 49.2 (46.1, 52.4) 42.5 (39.1, 46.2)
Testosterone (nmol/l) 0.95 (0.86, 1.05) 0.89 (0.78, 1.02)
Prolactin (mIU/l) 192 (177, 209) 193 (174, 213)
IGF-I (ng/ml) 144 (137, 152) 157 (146, 168)
IGF-I:IGFBP3 molar ratio 0.175 (0.166, 0.184) 0.199 (0.187, 0.213)
IGF-II (ng/ml) 896 (857, 938) 742 (698, 789)
IGF-II:IGFBP3 molar ratio 1.09 (1.04, 1.13) 0.94 (0.89, 1.00)
IGFBP3 (ng/ml) 4286 (4125, 4452) 4097 (3920, 4282)
IGF, insulin-like growth factor; IGFBP, IGF binding protein. aData presented as mean (standard deviation) or percentage. bData presented as 
median (25th to 75th percentiles). cData presented as geometric mean (95% confidence interval). dArithmetic mean (variable was not log 
transformed).Available online http://breast-cancer-research.com/content/11/3/R38
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ethnic groups (t-test P = 0.93). Breast cancer risk factor dis-
tributions in Afro-Caribbean women relative to Caucasian
women suggest a more protective risk profile for most factors,
characterised by later menarche, earlier age at first birth,
higher parity, earlier menopause and lower use of exogenous
hormones (Table 1). The major exception to this is BMI, for
which the mean in Afro-Caribbean women was 3.2 kg/m2
higher than that in Caucasian women (95% CI: 1.8, 4.5).
On average the percentage mammographic density was lower
in Afro-Caribbean women compared with Caucasian women
(median 8.3% compared with 16.2%; Table 1). This lower per-
cent density is composed of a smaller absolute dense area (by
4 cm2) and a much larger nondense area, and, consequently,
a much larger total breast area (difference in medians of over
50 cm2).
Mean plasma biomarker levels also revealed large ethnic differ-
ences (Table 1), which persisted after adjustment for process-
ing batch and age (Table 2). Leptin, oestrogens, IGF-I and
IGF-I:IGFBP3 molar ratios were all significantly higher
amongst Afro-Caribbean women than Caucasian women; in
particular, levels of oestradiol were 31% higher (95% CI:
12%, 52%) and levels of oestrone were 13% higher (95% CI:
1%, 27%). In the opposite direction, testosterone (although
not statistically significant), SHBG, IGF-II and IGF-II:IGFBP3
molar ratios were lower by 6%, 14%, 17% and 14%, respec-
tively, but there was no evidence of ethnic differences in
IGFBP-3 or prolactin (Table 2).
In an attempt to account for these differences, the lifestyle risk
factors presented in Table 1 were examined as biomarker
determinants (mutually adjusted for each other and for ethnic-
ity), for which only the statistically significant associations are
summarised here. BMI was strongly positively associated with
levels of oestradiol (total and free), oestrone and leptin but was
inversely associated with levels of SHBG. Both total and free
oestradiol levels were lower in nulliparous compared with
parous women, and among parous women they were lower in
women who had a later age at first live birth. There was also
Table 2
Comparison of plasma biomarkers and mammographic measures in Afro-Caribbean women compared with Caucasian women
Adjustmenta
Age and batch Age, batch and BMI Age, batch, BMI and breast cancer risk factorsb
Plasma biomarkerc
Leptin (ng/ml)d 6.8 (4.8, 8.9)**** 3.2 (1.7, 4.7)**** 3.6 (1.9, 5.2)****
Oestradiol (pmol/l) 1.31 (1.12, 1.52)**** 1.11 (0.96, 1.29) 1.11 (0.94, 1.31)
Free oestradiol (pmol/l) 1.39 (1.17, 1.65)**** 1.11 (0.95, 1.30) 1.11 (0.94, 1.32)
Oestrone (pmol/l) 1.13 (1.01, 1.27)** 1.05 (0.93, 1.18) 1.05 (0.93, 1.19)
SHBG (nmol/l) 0.86 (0.78, 0.96)*** 0.98 (0.89, 1.08) 0.96 (0.86, 1.07)
Testosterone (nmol/l) 0.94 (0.80, 1.11) 0.88 (0.74, 1.03) 0.86 (0.72, 1.03)
Prolactin (mIU/l) 1.02 (0.90, 1.16) 1.04 (0.91, 1.19) 1.00 (0.87, 1.16)
IGF-I (ng/ml) 1.09 (1.00, 1.19)** 1.13 (1.03, 1.24)*** 1.12 (1.01, 1.24)**
IGF-I:IGFBP-3 molar ratio 1.13 (1.04, 1.23)*** 1.20 (1.10, 1.30)*** 1.20 (1.10, 1.32)***
IGF-II (ng/ml) 0.83 (0.77, 0.89)**** 0.82 (0.76, 0.89)**** 0.82 (0.76, 0.90)****
IGF-II:IGFBP-3 molar ratio 0.86 (0.80, 0.92)**** 0.87 (0.81, 0.94)** 0.89 (0.82, 0.96)**
IGFBP-3 (ng/ml) 0.96 (0.91, 1.02)* 0.94 (0.89, 1.00)** 0.93 (0.87, 0.99)**
Mammographic measurese
Mammographic density (%) -5.4 (-7.8, -3.0)**** -2.5 (-5.1, 0.2)* -0.8 (-3.7, 2.2)
Dense area (cm2) -2.7 (-6.9, 1.4) -1.9 (-6.4, 2.7) 0.7 (-4.4, 5.8)
Nondense area (cm2) 50.5 (33.2, 67.8)*** 19.6 (7.7, 31.5)*** 15.7 (3.1, 28.3)**
Total breast area (cm2) 48.7 (31.3, 66.0)**** 18.7 (6.3, 31.1)*** 17.0 (3.6, 30.5)**
IGF, insulin-like growth factor; IGFBP, IGF binding protein; SHBG, sex hormone binding globulin. aAdjustment made for age at blood collection 
and processing batch (or age at mammography) in all models, in addition to listed factors. bAge at menarche, parity, age at first birth, smoking, age 
at menopause. cData presented as ratio (95% confidence interval) of mean levels (Afro-Caribbean:Caucasian). dArithmetic scale (absolute 
differences reported as leptin did not need to be log-transformed). eData presented as difference (95% confidence interval) in means (Afro-
Caribbean-Caucasian). *P < 0.1, **P < 0.05, ***P < 0.01, ****P < 0.001.Breast Cancer Research    Vol 11 No 3    McCormack et al.
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weak evidence that free oestradiol levels were lower in women
who had a later menarche, with levels estimated to be 4%
lower for every 1-year delay in menarche (95% CI: -1%, 8%).
There was no evidence that any other factors influenced oes-
trogen, SHBG or leptin levels. Testosterone levels were 34%
higher (95% CI: 1%, 78%) in current smokers than in non-
smokers and there was weak evidence that the levels were
higher in women with higher BMI. IGF-I levels were 17% lower
(95% CI: 2%, 30%) in women with a BMI over 30 kg/m2 com-
pared with those with a BMI of under 22 kg/m2. We did not
find any determinants of prolactin, IGF-II or IGFBP3.
As the distribution of the main determinants of biomarker lev-
els (that is, BMI, age at first birth, age at menarche and smok-
ing) also exhibit ethnic differentials (Table 1), the ethnic
differences in biomarker levels were largely attenuated upon
adjustment for these lifestyle risk factors and, in particular, for
BMI (Table 2). Greatly increased leptin and oestradiol levels in
Afro-Caribbean women compared with Caucasian women
were partly accounted for by their higher mean BMI, although
after full adjustment this ethnic group still had 3.6 ng/ml (95%
CI: 1.9, 5.2) higher leptin levels and 11% (95% CI: -6%, 31%)
higher oestradiol levels. Higher oestrone and lower testoster-
one and SHBG levels were entirely accounted for by differ-
ences in BMI distributions. In contrast, the ethnic differences
in IGFs became larger after adjustment for lifestyle risk factors.
Higher crude IGF-I and IGF-I:IGFBP3 levels in Afro-Caribbean
women were negatively confounded by BMI, as BMI is higher
in the Afro-Caribbean women but it is associated with lower
IGF levels. After full adjustment, therefore, IGF-I:IGFBP3 molar
ratios were 20% higher in Afro-Caribbean women (95% CI:
10%, 32%). IGF-II and IGFBP3 levels were lower in Afro-Car-
ibbean women than in Caucasian women, and adjustment for
BMI and other factors did not explain this difference.
The estimated effect of a twofold increase in each biomarker
on percentage mammographic density and areas of dense and
nondense tissue are presented in Table 3 (all tests of depar-
tures from linearity and of interactions with ethnicity were non-
significant). Age-adjusted (at mammogram and blood
collection), batch-adjusted and ethnicity-adjusted associa-
tions are firstly presented, and thereafter additional adjustment
for BMI is made. Associations of leptin, total and free oestra-
diol and testosterone with percentage mammographic density
showed similar patterns: before adjusting for BMI, there was a
strong positive association with nondense area that was
reflected in a strong inverse association with percent density,
but no associations were observed with dense area. These
associations were entirely explained by BMI. The percentage
mammographic density was similarly lower in women with
higher oestrone levels, but this association resulted not just
from a larger nondense area but also from a smaller dense
Table 3
Difference in mammographic measures associated with a twofold increase in plasma biomarker levels
Mammographic density (%) Dense area (cm2) Nondense area (cm2)
Adjustment 1a Adjustment 2b Adjustment 1a Adjustment 2b Adjustment 1a Adjustment 2b
Leptinc 
(per 9 ng/ml increase)
-4.2 (-5.6, 2.8)**** -1.2 (-3.4, 0.9) -1.5 (-4.0, 1.0) -0.6 (-4.3, 3.1) 41.0 (33.1, 49.0)**** 10.1 (1.2, 18.9)**
Oestradiol -3.1 (-4.5, -1.6)**** -1.2 (-2.8, 0.4) -1.8 (-4.3, 0.7) -1.3 (-4.1, 1.4) 22.4 (13.8, 31.1)**** 2.9 (-3.6, 9.5)
Free oestradiol -3.2 (-4.5, -1.8)**** -1.2 (-2.7, 0.4) -1.9 (-4.1, 0.4) -1.5 (-4.1, 1.1) 24.1 (16.4, 31.7)**** 2.4 (-3.7, 8.6)
Oestrone -3.9 (-5.9, -1.9)**** -2.0 (-4.1, 0.0)* -3.6 (-6.8, -0.4)** -2.9 (-6.3, 0.5)* 20.6 (8.4, 32.8)*** 1.0 (-7.3, 9.4)
SHBG 4.1 (1.4, 6.9)*** 0.2 (-2.4, 2.8) 2.3 (-1.7, 6.2) 1.5 (-2.9, 5.9) -28.9 (-38.9, -
18.9)****
0.2 (-9.3, 9.7)
Testosterone -2.2 (-3.7, -0.7)*** -1.4 (-2.9, 0.1)* -1.8 (-4.2, 0.6) -1.7 (-4.1, 0.8) 11.3 (2.8, 19.7)*** 3.4 (-2.5, 9.3)
Prolactin 2.2 (-0.1, 4.4)* 1.7 (-0.3, 3.7)* 1.8 (-1.5, 5.2) 1.7 (-1.6, 5.0) -11.2 (-21.0, -1.4)** -7.7 (-14.6, -0.8)**
IGF-I 2.0 (-1.1, 5.0) 0.8 (-1.9, 3.5) 0.5 (-3.9, 4.9) 0.3 (-4.1, 4.7) -10.6 (-24.3, 3.0) -1.6 (-11.7, 8.5)
IGF-I:IGFBP-3 molar 
ratio
2.2 (-1.1, 5.5) -0.2 (-3.1, 2.7) 0.7 (-4.0, 5.5) 0.0 (-4.7, 4.8) -14.3 (-28.7, 0.1)* 5.0 (-6.3, 16.3)
IGF-II -0.9 (-4.3, 2.4) -1.0 (-4.1, 2.0) -2.6 (-7.5, 2.2) -2.8 (-7.6, 2.0) -1.1 (-18.2, 16.0) 0.0 (-12.0, 12.0)
IGF-II:IGFBP-3 molar 
ratio
-1.2 (-4.7, 2.4) -2.7 (-5.8, 0.4) -2.8 (-8.0, 2.4) -3.7 (-8.8, 1.4) -4.3 (-22.4, 13.8) 9.7 (-3.8, 23.2)
IGFBP-3 0.2 (-4.2, 4.5) 2.3 (-2.0, 6.5) -0.3 (-6.8, 6.2) -0.6 (-6.1, 7.3) 4.3 (-17.7, 26.4) -12.7 (-27.1, 1.7)*
Statistics presented as difference (95% confidence interval). IGF, insulin-like growth factor; IGFBP, IGF binding protein; SHBG, sex hormone 
binding globulin. aAdjusted for age at blood collection and age at mammography, batch, and ethnic group. bAdjusted for age at blood collection 
and age at mammography, batch, ethnic group, and body mass index. cArithmetic scale, leptin was not log transformed. *P < 0.1, **P < 0.05, ***P 
< 0.01, ****P < 0.001.Available online http://breast-cancer-research.com/content/11/3/R38
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area. Even after adjustment for BMI, a twofold difference in
oestrone levels was associated with a smaller dense area by
2.9 cm2 (95% CI: -0.5, 6.3). The strong inverse association of
BMI with SHBG was mirrored in the inverse association of
SHBG with nondense area (with a corresponding association
in the opposite direction with percent density), an association
that was explained by BMI. Further adjustment for other breast
cancer risk factors did not change the BMI-adjusted estimates
substantially (data not shown).
Women with higher prolactin levels had higher mean percent-
age mammographic density, both before and after adjusting
for BMI. Twofold-higher prolactin levels were associated with
2.2% higher percent density (95% CI: -0.1, 4.4) (borderline
statistically significant). This association resulted from both a
positive association with the area of dense tissue and an
inverse association with the nondense area. There was no evi-
dence that this, or any other, association differed between the
two ethnic groups.
There was no evidence of an association of either IGF-I, IGF-II
or IGFBP-3 (or their molar ratios) with any of the measures of
mammographic density (relative or absolute) whether or not
BMI was adjusted for.
Returning to ethnic differences in mammographic density, the
age-adjusted mean percentage mammographic density was
lower in Afro-Caribbean women than in Caucasian women, by
5.4% (95% CI: 3.0, 7.8). This difference was greatly attenu-
ated upon adjustment for BMI (Table 2 and Figure 1) and fur-
ther adjustment for blood biomarkers one at a time did not
greatly affect this estimate, which was only attenuated to the
null after controlling for reproductive breast cancer risk fac-
tors. These findings are not surprising given that the biomark-
ers that revealed ethnic differences (oestrogens and IGFs)
were not associated with percentage mammographic density,
and given that prolactin, which had a borderline positive asso-
ciation with percent density, exhibited no ethnic differences.
Discussion
In this study of postmenopausal Caucasian and Afro-Carib-
bean women, higher levels of leptin, oestradiol (total and free),
oestrone and testosterone were associated with lower per-
centage mammographic density, resulting from strong positive
associations with the fatty area of the breast and no associa-
tions with dense area. The associations with percent density
were attenuated to the null once BMI had been controlled for.
Separate analyses of the effects on dense area, nondense
area and percent density were informative and are particularly
important when BMI is a strong confounder, as in the case of
sex hormones that are adipose-derived in postmenopausal
women. Determinants of percentage breast density that arise
from an impact on the area of dense tissue, with or without a
simultaneous effect on the area of nondense tissue, are more
likely to be the relevant factors for breast cancer aetiology as
the dense area represents stromal and epithelial tissue where
breast cancers arise. Such factors may act through stromal
and epithelial proliferation or breast involution. IGFs were not
associated with any components of mammographic density
either before or after adjusting for BMI. There was borderline
statistically significant evidence that lower oestrone and
higher prolactin levels were associated with higher percent-
age mammographic density. These biomarkers did not differ
between ethnic groups, however, so they did not contribute to
ethnic differences in percent density.
These results are largely consistent with those from previous
studies of postmenopausal women. For oestradiol (total or
free) and oestrone, inverse associations with percent density
were attenuated upon adjustment for a measure of body size
(BMI or waist circumference) in several previous studies
[10,16-18], but with some exceptions. Aiello and colleagues
found that inverse associations of oestrone and oestradiol
(total and free) remained after adjustment for percentage body
fat, but that this association was restricted to former hormone
therapy users (all women were not taking hormone therapy at
the time of blood/mammogram) – especially amongst women
with hormone therapy use within the past 5 years, suggesting
a long-lasting or residual effect of the exogenous hormones
[10]. In a study by Boyd and colleagues, an inverse associa-
tion of free oestradiol with both percent density and absolute
dense area persisted after adjusting for waist circumference
[11]. The only study to have found positive associations of
oestrogens (oestrone and oestradiol) with percent density
Figure 1
Ethnic differences in percentage mammographic density and dense  area Ethnic differences in percentage mammographic density and dense 
area. Ethnic differences in percentage mammographic density (%) and 
dense area between Afro-Caribbean and Caucasian women, after 
adjusting for age, body mass index (BMI) and each plasma biomarker 
separately. IGF, insulin-like growth factor; IGFBP, IGF binding protein; 
MR, molar ratios; SHBG, sex hormone binding globulin.Breast Cancer Research    Vol 11 No 3    McCormack et al.
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after BMI adjustment is that of Greendale and colleagues [12].
Our finding of a negative association with oestrone is surpris-
ing, but was only borderline statistically significant and may be
a false positive finding.
These findings do not, however, rule out the possibility that
breast density is affected by sex steroids. Most of the studies
that have examined these associations have been cross-sec-
tional in nature and have been carried out in postmenopausal
women, whereas higher premenopausal levels of sex steroids
are more likely to capture the aetiologically relevant exposure
period. Lower mammographic density in more parous women,
in older women and after the menopausal transition are sug-
gestive of a hormonal basis to density. Furthermore, the strik-
ing parallels between the age profiles of percentage
mammographic density, several sex steroids and Pike and col-
leagues' proposed model for the rate of breast tissue ageing
[19] may result from common underlying biological processes.
Studies of sex hormones in relation to percent density at pre-
menopausal ages are needed, but are hampered by the una-
vailability of routinely conducted mammography at younger
ages as well as by the difficulties in capturing a woman's aver-
age exposures to oestrogens given the large changes in hor-
monal levels across the menstrual cycle.
Neither IGF-I, IGF-II or their binding proteins were related to
density; therefore, although their mean levels differed greatly
by ethnicity, these factors did not explain ethnic differentials in
percentage or absolute mammographic density. These find-
ings are in agreement with several findings in postmenopausal
women of null associations [10,20-23], although one study
has reported a positive association [24]. As IGF-I is a breast
cancer risk factor only at premenopausal ages, null associa-
tions with mammographic density in postmenopausal women
may not be unexpected. IGF-I may still be a determinant of
mammographic density at premenopausal ages, however,
since positive associations have been observed in younger
women [25] and IGF SNPs were reported to be associated
with percent density irrespective of menopausal status [26].
Previous investigations into the effect of prolactin on mammo-
graphic density have been inconsistent – two found positive
associations [11,27] and two were null [16,28]. Our findings
do not help greatly to clarify this association, as we observed
a weak positive association that was only significant at the
10% level. The circadian rhythm of prolactin, however, would
give rise to large measurement error, reduced power and
attenuation of regression slopes if a relationship truly exists.
Although prolactin's role in breast development and lactation
is well known, few determinants of this hormone other than
parity are known [29]. It is plausible that mammographic den-
sity is on the causal pathway to breast cancer, as prolactin
increases mitosis in the breast [28]. Further research into the
prolactin–mammographic density association as well as the
factors affecting prolactin levels are warranted in order to fur-
ther clarify these associations.
The present study benefited from an ethnically diverse study
population whose varied lifestyles give rise to very heterogene-
ous biomarker distributions in which, if associations exist,
there was a wider range of exposures and outcomes within
which they could be detected. The women were from a popu-
lation-based screening programme and are representative of
their ethnic groups [9]. We do not know the characteristics of
the nonresponders, but it is possible that if factors associated
with nonresponse (such as socioeconomic status) are also
associated with breast density or biomarker levels, then the
differential response rates by ethnic group might have biased
ethnic differences in these levels. Associations between
biomarkers and mammographic density, however – the focus
of this paper – will not be affected as the observed associa-
tions are internal to the group of participating women.
Ethnic diversity included greatly differing BMI distributions,
which, in the context of mammographic density, act as strong
confounders. Coupled with this, adipose tissue is a major
source of oestrogens in postmenopausal women, so adjust-
ment for BMI is essential to disentangle any hormone – density
associations that are not due to BMI. There remains the possi-
bility of residual confounding as BMI was calculated from self-
reported height and weight. Measurements at both the time of
mammography and blood collection would have been more
suitable. Measurement error may also attenuate results, espe-
cially for oestrone and prolactin that were less repeatable;
however, error in the mammographic measurements was
reduced through the use of average values across four films.
The lag time between mammography and blood collection
(approximately 1.7 years later) was not ideal and may have
diluted findings, especially if hormone levels changed at differ-
ent rates (for example, between younger and older postmeno-
pausal women), but for the majority of women changes in
hormone levels at these ages are likely to be small. The study
was conducted in this fashion so as not to interfere with breast
screening uptake. We did not adjust for the increased chance
of false positive results from examining many exposures but, as
the findings are essentially null, correction for multiple testing
would not have changed the overall interpretation.
Cumulus-derived measures of breast density are area based
and are a somewhat crude simplification of the three-dimen-
sional breast. Two women with the same dense area may have
very different volumes of dense tissue if the breast thickness,
breast size and degree of breast compression differ. Given the
lack of a validated volumetric approach to breast density
measurement that can be applied retrospectively to digitised
films, however, the use of Cumulus, a well-established
method, was considered the best option currently available.Available online http://breast-cancer-research.com/content/11/3/R38
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Lower breast cancer incidence rates, as reflected in marginally
lower percentage mammographic density, in Afro-Caribbean
women were not explained by levels of sex hormones, IGFs or
prolactin as measured at a single time point postmenopau-
sally. This measure, however, may not capture differences at
younger ages or across the life-course. Lower density and
breast cancer incidence rates could still be due to lower
cumulative exposure to oestrogens in particular. At premeno-
pausal ages, higher BMI is associated with lower oestrogen
levels, and, combined with a later menarche and higher parity,
total exposure to oestrogens at premenopausal ages is likely
to be much lower in Afro-Caribbean women compared with
Caucasian women. We have not been able to examine hor-
mone–density associations at these ages as screening by
mammography is only available to women aged 50 years and
older in the UK.
Conclusions
Mammographic density has one of the strongest associations
with breast cancer risk, but the biological mechanism relating
it to breast cancer is not clear. Greater density must result
from greater rates of stromal proliferation, epithelial prolifera-
tion and/or slower rates of involution [30]. The chemical mark-
ers or processes that may influence these rates, and thus
density, are not well identified.
Studies of first-generation migrants, as shown here, provide
useful populations in which heterogeneity can be captured.
Herein, despite large differences in breast cancer biomarkers
(sex steroid and IGFs) between Afro-Caribbean women and
Caucasian women, we did not observe associations of these
biomarkers with postmenopausal mammographic density after
controlling for the large confounding effect of BMI. The possi-
bility remains, however, that mammographic density is influ-
enced by these hormones, but that the critical period of
exposure is when their levels are much higher, at premenopau-
sal ages.
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